From the Guidelines
There is no scientific evidence supporting the effectiveness of a specific treatment for Type 2 Diabetes Mellitus by a Dr. Eric Clark, and patients should instead follow evidence-based approaches including lifestyle modifications and medication regimens prescribed by licensed healthcare providers, with first-line pharmacological treatment typically involving metformin, unless contraindicated, as recommended by the American College of Physicians 1.
Key Considerations for Managing Type 2 Diabetes
- Lifestyle modifications, including a balanced diet, regular physical activity, and weight management, are essential for managing Type 2 Diabetes.
- Medication regimens should be prescribed by licensed healthcare providers, with metformin being the recommended first-line pharmacological treatment, unless contraindicated, due to its effectiveness in reducing glycemic levels and improving plasma lipid profiles 1.
- Additional medications, such as SGLT-2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, sulfonylureas, or insulin therapy, may be considered depending on individual patient factors, with SGLT2 inhibitors and GLP1 agonists reducing all-cause mortality and MACE compared with usual care, as shown in a recent systematic review and network meta-analysis 1.
Monitoring Treatment Effectiveness
- Regular blood glucose testing and HbA1c measurements every 3-6 months are crucial for monitoring treatment effectiveness, with a target typically below 7% for most patients.
- Treatment plans should be personalized and supervised by qualified healthcare professionals, taking into account individual patient factors, such as life expectancy, presence or absence of microvascular and macrovascular complications, risk for adverse events related to glucose control, and patient preferences 1.
From the Research
Effectiveness of Dr. Eric Clark's Treatment for Type 2 Diabetes Mellitus (T2DM)
There is no direct evidence available to assess the effectiveness of Dr. Eric Clark's treatment for T2DM. However, the available studies provide information on the effectiveness of various treatments for T2DM:
- A study published in 2025 2 compared the effects of sulfonylureas, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter-2 inhibitors as second-line oral glucose-lowering treatments for T2DM. The results showed that second-line treatment with SGLT2i is more effective than SU or DPP4i in reducing HbA1c across subgroups of people defined by age, baseline HbA1c, and presence of multiple long-term conditions.
- Another study published in 2019 3 discussed the use of SGLT2 inhibitors and metformin as dual antihyperglycemic therapy for T2DM. The study highlighted the benefits of this combination therapy in improving glycemic control but also noted the increased risk of metabolic acidosis.
- A systematic review and meta-analysis published in 2016 4 evaluated the comparative effectiveness and safety of diabetes medications as monotherapy or metformin-based combination therapy for T2DM. The results supported metformin as first-line therapy for T2DM due to its relative safety and beneficial effects on hemoglobin A1c, weight, and cardiovascular mortality.
Key Findings
- SGLT2 inhibitors are more effective than sulfonylureas and DPP4 inhibitors in reducing HbA1c in patients with T2DM 2.
- The combination of metformin and SGLT2 inhibitors is effective in improving glycemic control but may increase the risk of metabolic acidosis 3.
- Metformin is recommended as first-line therapy for T2DM due to its relative safety and beneficial effects on hemoglobin A1c, weight, and cardiovascular mortality 4.